Bachem stock extends its focus on growth and margin

Bachem Holding AG (CH0012530207) remains a Swiss small-cap name where the numbers matter more than the narrative. Its investor materials and market context point to a business that is measured by revenue, profitability, and leverage rather than by headlines alone.

Revenue and margin still matter

The company reported revenue of CHF 496.7 million for 2025, alongside EBITDA of CHF 115.3 million and an EBITDA margin of 23.2%. Those figures give investors a clear benchmark for the current operating base and show how much room there is between scale and profitability.

Compared with 2024, revenue was up from CHF 444.3 million, while EBITDA rose from CHF 93.7 million. That is a quantified improvement of CHF 52.4 million in sales and CHF 21.6 million in EBITDA, a comparison that matters more than broad language about momentum.

Debt and cash flow stay relevant

Net debt stood at CHF 464.5 million at the end of 2025, while free cash flow reached CHF 34.6 million. For a company with growth ambitions, the combination of positive cash generation and a debt load of that size remains one of the central analytical questions.

The same 2025 reporting set shows that Bachem’s performance is not a one-line story. Revenue, EBITDA, margin, debt, and free cash flow move together, which is why the balance sheet can matter as much as the top line.

Investor materials frame the picture

On 24 July 2026, the most relevant public entry point for Bachem remains its investor relations page, which collects reports, presentations, and calendar material in one place. That is the right place to track whether the 2025 base is translating into the next reporting step.

For market readers, the practical point is simple: the 2025 numbers already define the discussion, and the next update will be judged against them.

Peptide platform remains the product anchor

Bachem’s peptide and oligonucleotide manufacturing platform is the commercial anchor behind those 2025 figures. The company’s business depends on custom synthesis, capacity utilization, and the flow of development programs into later-stage production, so the operating metrics carry more weight than any single product label.

That also explains why the revenue and EBITDA comparison with 2024 matters. A business built around specialized pharmaceutical ingredients is judged on how efficiently it converts demand into margin, and the 23.2% EBITDA margin is the number that frames that debate.

No dated quote to anchor

Bachem shares traded in Switzerland, but this article keeps the market frame tied to evidenced 2025 operating data and the company investor page rather than to an unverified intraday quote. The 2025 revenue of CHF 496.7 million, EBITDA of CHF 115.3 million, and net debt of CHF 464.5 million remain the cleanest published anchors for the current discussion.